Alemtuzumab and multiple sclerosis: therapeutic application. - Wikidata - awgldk - TriplyDB

Alemtuzumab and multiple sclerosis: therapeutic application.

Alemtuzumab and multiple sclerosis: therapeutic application.

http://www.wikidata.org/entity/Q37679919

about

Multiple sclerosis: the role of cytokines in pathogenesis and in therapies Clinical Update in Aspects of the Management of Autoimmune Thyroid Diseases Immunogenicity and other problems associated with the use of biopharmaceuticals.An update on the management of chronic inflammatory demyelinating polyneuropathy.Multiple sclerosis: pathogenesis and treatment.Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.Current and future therapies for multiple sclerosis.Drugs in development for relapsing multiple sclerosis.Monoclonal antibodies in treatment of multiple sclerosis.Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS.Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression.

P2860

Q27011014-2CA0F74A-7EC8-49A2-AED8-65F7E3C39403 Q28075859-6DACDDCE-B87A-4F9D-8E06-54027D056E49 Q33416851-6DDFAC81-C8E0-4C07-913B-E233834A0A6F Q34645179-53F889D2-A8A2-4959-9C87-6A8850BAF270 Q35151851-1A6A41FF-107F-4B73-8541-A1D8FCC6E0B5 Q35606563-C06BF574-F586-4E1A-ADFA-1263E476F5B7 Q37287769-5A2FE2E8-4F98-4DC1-925C-FD7E514D5D28 Q38101004-C78E7DAF-80EB-4FB3-BB8A-ED6ABB51598C Q38133865-16166AA4-0D0A-4917-BFFB-1C6FCA4C976B Q38150405-D688327B-0502-4885-8988-457662E7E6ED Q38252979-07F93D7D-924C-401B-A4E0-D6B366F138E0 Q39744600-645B18BC-B5C3-4E7E-8E1C-FF3C7DF8D981 Q41518158-0656784F-FB77-4C77-AB45-759CF677BB44

P2860

Alemtuzumab and multiple sclerosis: therapeutic application.

http://www.wikidata.org/entity/Q37679919

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Alemtuzumab and multiple sclerosis: therapeutic application.

@en

Alemtuzumab and multiple sclerosis: therapeutic application.

@nl

type

label

Alemtuzumab and multiple sclerosis: therapeutic application.

@en

Alemtuzumab and multiple sclerosis: therapeutic application.

@nl

prefLabel

Alemtuzumab and multiple sclerosis: therapeutic application.

@en

Alemtuzumab and multiple sclerosis: therapeutic application.

@nl

P1433

Q37679919-20612F26-73AB-4F1B-8307-C430316393D1

P1476

Q37679919-88015ED8-A1A6-4A78-9B55-3ACFE5EE529F

P2093

Q37679919-1166864D-CEC2-480B-9C48-F33651660406

Q37679919-84784E7C-6F47-4B15-AD8E-733F89CB8C6D

P2860

Q37679919-0348A582-DBAC-4BB1-878A-5443F130D51D

Q37679919-056A2E47-95D7-470C-A78C-44CFDCD564C4

Q37679919-10CCABE1-3F2F-4946-9C14-BC1CBE215D71

Q37679919-1B0FD46D-3541-4521-9FB2-3448AD1D009F

Q37679919-2217CE33-DB5E-4197-A5CC-D9137C140A16

Q37679919-2749BAEB-D07F-4025-B43A-4A94395D6666

Q37679919-2D52BCFA-89D4-4957-834A-D9F95F76B543

Q37679919-2E27974A-A617-47CC-8D82-C4A558201967

Q37679919-2EC990FA-E73F-4D62-A71C-C98B0557C017

Q37679919-2F4F8B27-8FC5-40F3-9455-FD45E8B33EA0

P304

Q37679919-022ACC66-EEDB-4DEB-83B2-B56E93B170FB

P31

Q37679919-D205C110-C7C5-495E-8957-AA9972FE97C6

P356

Q37679919-619EC3E4-C457-452C-822D-B343522BCD93

P407

Q37679919-EAB82C4E-A9E5-4AE0-9472-437A029B3FD4

P433

Q37679919-AED8DC16-BC48-4E41-87EA-EAF328A0DCA8

P478

Q37679919-D591BB91-6A64-49AB-8F87-761333587860

P50

Q37679919-2070373D-EA41-45EA-9CB8-612E567ED6C9

Q37679919-46A9B095-A5AF-4439-B578-689809D52ACD

P577

Q37679919-8F26EC32-5AFC-4852-86EC-166E6B632F40

P5875

Q37679919-A5AC5E04-4DCC-44F7-BCA9-ECE06F193104

P698

Q37679919-8DFC93F9-0AEB-42CE-8963-680DE7B133FB

P921

Q37679919-E35521AE-753B-4B23-888F-D9B168737FB2

P356

14712591003586806

P1433

Expert Opinion on Biological Therapy

P1476

Alemtuzumab and multiple sclerosis: therapeutic application.

@en

P2093

Alireza Minagar

http://www.w3.org/2001/XMLSchema#string

J Steven Alexander

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

Cd52, known as a major maturation-associated sperm membrane antigen secreted from the epididymis, is not required for fertilization in the mouse

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

Axonal transection in the lesions of multiple sclerosis

IL-17 family cytokines and the expanding diversity of effector T cell lineages

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis.

P304

421-429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712591003586806

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Mohammad Ali Sahraian

Robert Zivadinov

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41121266

http://www.w3.org/2001/XMLSchema#string

P698

20095876

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis